

2016-2018 Drug Discovery for Neurodegeneration Conferences

<https://neurodegenerationresearch.eu/survey/2016-2018-drug-discovery-for-neurodegeneration-conferences/>

Principal Investigators

FILLIT, HOWARD M.

Institution

ALZHEIMER'S DRUG DISCOVERY FOUNDATION

Contact information of lead PI

Country

USA

Title of project or programme

2016-2018 Drug Discovery for Neurodegeneration Conferences

Source of funding information

NIH (NIA)

Total sum awarded (Euro)

174311.9266

Start date of award

30/09/2015

Total duration of award in years

2

Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Dementia... Neurodegenerative... Neurosciences... Translational Research

Research Abstract

? DESCRIPTION (provided by applicant): There is a well-documented knowledge and resource gap in translating basic research into novel therapeutics. Outside of the pharmaceutical industry, there are very few opportunities for the next generation of scientific leaders to learn about the drug discovery and development process in general, and particularly for

neurodegenerative diseases. To meet this need, the Alzheimer's Drug Discovery Foundation (ADDF) developed the annual Drug Discovery for Neurodegeneration (DDND) conference, which has reached 1,252 participants since its inception in 2007. The ADDF requests a U13 Cooperative Agreement conference grant for three years of support for its DDND conference, scheduled for March 2016 in Miami, FL, March 2017 in San Diego, CA, and March 2018 in the Washington, D.C. metro area. The goals of these didactic conferences are clearly consistent with the initiatives set forth at the NIH's 2012 and 2015 Alzheimer's Disease Research Summit: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. These conferences will provide participants with fundamental knowledge and resources on developing new drugs to treat and prevent neurodegenerative diseases, and will address the challenges associated with the following sub-topics: (1) Embarking on a Drug Discovery Campaign; (2) Starting at the End: The Pharmacology-Chemistry Interface in Preclinical Drug Development; (3) Drug Discovery: From Lead to Clinical Candidate; (4) Strategies for CNS Targets: Case Study Examples; and (5) Commercialization Strategies: Developing Science into Products. Discussions will include relevant examples focused on small molecule and biologic development for Alzheimer's and related neurodegenerative diseases. Sessions will consist of 30 minute presentations with ample time for Q&A, and the program will include sessions for networking, partnering/mentoring, and posters presented by young investigators. With respect to public-private partnerships, the ADDF will invite 22 internationally recognized scientists from academia, industry and the NIH to serve as chairs or speakers. We have assembled a Scientific Advisory Committee that has agreed to participate for the next three years to assist in the development of the conferences. It is anticipated that these conferences will serve 150 scientists annually from diverse backgrounds, including women, minorities, young/junior investigators and graduate students.

Further information available at:

Types:

Investments < €500k

Member States:

United States of America

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A